NCT04068467 is a NA clinical trial of Smartphone App in Schizophrenia, sponsored by University of Washington.

Who is sponsoring NCT04068467?

NCT04068467 is sponsored by University of Washington.

What drugs are being tested in NCT04068467?

Interventions in NCT04068467: Smartphone App, Waitlist Control.

What condition does NCT04068467 study?

NCT04068467 studies Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder, Bipolar Disorder.

Is NCT04068467 still recruiting?

NCT04068467 is currently completed. Last updated 11 August 2021.

Last reviewed 2021-08-11 · How we verify

NCT04068467

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of mHealth for Serious Mental Illness

Completed NA Last updated 11 August 2021

What this trial tests

NA trial testing Smartphone App in Schizophrenia in 315 participants. Completed in 1 May 2021.

Timeline

6 January 2020

Primary endpoint
1 May 2021

1 May 2021

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	supportive care
Enrollment	315
Start date	6 January 2020
Primary completion	1 May 2021
Estimated completion	1 May 2021
Sites	1 location across United States

Drugs / interventions tested

Smartphone App
Waitlist Control

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Schizoaffective Disorder — all drugs for Schizoaffective Disorder →
Major Depressive Disorder — all drugs for Major Depressive Disorder →
Bipolar Disorder — all drugs for Bipolar Disorder →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Schizophrenia or Schizoaffective Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a waitlist control trial evaluating the acceptability and preliminary efficacy of a smartphone application with people with mental illness.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A Smartphone Intervention for People With Serious Mental Illness: Fully Remote Randomized Controlled Trial of CORE.
Ben-Zeev D, Chander A, Tauscher J, Buck B, et al · · 2021 · cited 35× · PMID 34766913 · DOI 10.2196/29201

Verify or expand the search:

Other trials of Smartphone App

Trials testing the same drug.

NCT07165561 — Evaluation of an App for Young People With Suicidal Thoughts · NA · recruiting
NCT05785533 — A Mobile Recovery Guidance App for Children and Young Adults With Acute Ankle Inversion Injuries · NA · recruiting
NCT06114199 — Enhancing the Effectiveness of Home-delivery Based Produce Prescription Program Implementation Strategies · NA · recruiting
NCT06923033 — Aim 1: App for Reducing Cravings to Smoke · NA · completed
NCT04896593 — Mobile Technology for Reducing and Preventing Adolescent Suicide · NA · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other University of Washington trials

Trials by the same sponsor.

NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04068467 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Washington
Last refreshed: 11 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04068467.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing